Custos da doença atribuíveis à hipercolesterolémia em Portugal

Bibliographic Details
Main Author: Gouveia, Miguel
Publication Date: 2004
Other Authors: Borges, Margarida, Costa, João, Oliveira, Eduardo Infante de, David, Cláudio, Carneiro, António Vaz
Format: Article
Language: por
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10451/32920
Summary: Cardiovascular diseases are the main cause of death in Portugal, in developed countries and, indeed, worldwide. Hypercholesterolemia is a major risk factor for these diseases, including ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. This paper reports the results of a study of the cost of illness associated with hypercholesterolemia and the costs directly attributable to hypercholesterolemia in Portugal, estimated from data for the year 2000. The results indicate that the cost of the health care provided to deal with illnesses associated with hypercholesterolemia was Euros 735.9 million (direct costs) and the costs of lost production due to disability of patients of working age was Euros 74.82 million (indirect costs). The costs attributable to hypercholesterolemia, those that would be avoided if hypercholesterolemia were completely eliminated, amount to Euros 358.84 million in direct costs and Euros 28.31 million in indirect costs. These results confirm that hypercholesterolemia is a source of major health costs. This means that hypercholesterolemia deserves special attention from those who formulate health policy and should be given priority in implementing such policies.
id RCAP_3941dcecc0e882612a0161bab38a8b11
oai_identifier_str oai:repositorio.ulisboa.pt:10451/32920
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Custos da doença atribuíveis à hipercolesterolémia em PortugalCosts of illness due to hypeercholesterolemia in PortugalCardiovascular diseaseCoronary heart diseaseCerebrovascular diseaseDirect costsIndirect costsCosts of illnessEconomic studiesEvidence-based cardiologyCardiovascular diseases are the main cause of death in Portugal, in developed countries and, indeed, worldwide. Hypercholesterolemia is a major risk factor for these diseases, including ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. This paper reports the results of a study of the cost of illness associated with hypercholesterolemia and the costs directly attributable to hypercholesterolemia in Portugal, estimated from data for the year 2000. The results indicate that the cost of the health care provided to deal with illnesses associated with hypercholesterolemia was Euros 735.9 million (direct costs) and the costs of lost production due to disability of patients of working age was Euros 74.82 million (indirect costs). The costs attributable to hypercholesterolemia, those that would be avoided if hypercholesterolemia were completely eliminated, amount to Euros 358.84 million in direct costs and Euros 28.31 million in indirect costs. These results confirm that hypercholesterolemia is a source of major health costs. This means that hypercholesterolemia deserves special attention from those who formulate health policy and should be given priority in implementing such policies.As doenças cardiovasculares são a principal causa de morte em Portugal, na generalidade dos países desenvolvidos e de facto em todo o mundo. A hipercolesterolémia é um dos principais factores de risco de tais doenças, incluindo a doença isquémica do coração, a doença vascular cerebral e a doença vascular periférica. Este artigo reporta os resultados de um estudo dos custos das doenças associadas à hipercolesterolémia e dos custos directamente atribuíveis à hipercolesterolémia estimados com base nos dados do ano 2000 em Portugal. Os resultados obtidos apontam para que as doenças associadas à hipercolesterolémia tenham requerido cuidados de saúde com o custo de a735,9 milhões (custos directos) e gerado perdas de produção por incapacidade dos doentes em idade activa de a 74,82 milhões (custos indirectos). Os custos atribuíveis à hipercolesterolémia, aqueles que seriam evitados se a hipercolesterolémia fosse completamente eliminada, somaram um total a 358,84 milhões para os custos directos e a 28,31 milhões para os custos indirectos. Estes resultados confirmam a ideia de a hipercolesterolémia ser uma fonte de custos de grande dimensão. Essa é uma razão para que a hipercolesterolémia mereça a atenção devida dos decisores das políticas de saúde e a prioridade correspondente na formulação de tais políticas.Sociedade Portuguesa de CardiologiaRepositório da Universidade de LisboaGouveia, MiguelBorges, MargaridaCosta, JoãoOliveira, Eduardo Infante deDavid, CláudioCarneiro, António Vaz2018-04-20T14:24:24Z20042004-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/32920porRev Port Cardiol 2004;23 (7-8):1037-10540870-2551info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-17T13:53:02Zoai:repositorio.ulisboa.pt:10451/32920Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T02:56:56.341460Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Custos da doença atribuíveis à hipercolesterolémia em Portugal
Costs of illness due to hypeercholesterolemia in Portugal
title Custos da doença atribuíveis à hipercolesterolémia em Portugal
spellingShingle Custos da doença atribuíveis à hipercolesterolémia em Portugal
Gouveia, Miguel
Cardiovascular disease
Coronary heart disease
Cerebrovascular disease
Direct costs
Indirect costs
Costs of illness
Economic studies
Evidence-based cardiology
title_short Custos da doença atribuíveis à hipercolesterolémia em Portugal
title_full Custos da doença atribuíveis à hipercolesterolémia em Portugal
title_fullStr Custos da doença atribuíveis à hipercolesterolémia em Portugal
title_full_unstemmed Custos da doença atribuíveis à hipercolesterolémia em Portugal
title_sort Custos da doença atribuíveis à hipercolesterolémia em Portugal
author Gouveia, Miguel
author_facet Gouveia, Miguel
Borges, Margarida
Costa, João
Oliveira, Eduardo Infante de
David, Cláudio
Carneiro, António Vaz
author_role author
author2 Borges, Margarida
Costa, João
Oliveira, Eduardo Infante de
David, Cláudio
Carneiro, António Vaz
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Gouveia, Miguel
Borges, Margarida
Costa, João
Oliveira, Eduardo Infante de
David, Cláudio
Carneiro, António Vaz
dc.subject.por.fl_str_mv Cardiovascular disease
Coronary heart disease
Cerebrovascular disease
Direct costs
Indirect costs
Costs of illness
Economic studies
Evidence-based cardiology
topic Cardiovascular disease
Coronary heart disease
Cerebrovascular disease
Direct costs
Indirect costs
Costs of illness
Economic studies
Evidence-based cardiology
description Cardiovascular diseases are the main cause of death in Portugal, in developed countries and, indeed, worldwide. Hypercholesterolemia is a major risk factor for these diseases, including ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. This paper reports the results of a study of the cost of illness associated with hypercholesterolemia and the costs directly attributable to hypercholesterolemia in Portugal, estimated from data for the year 2000. The results indicate that the cost of the health care provided to deal with illnesses associated with hypercholesterolemia was Euros 735.9 million (direct costs) and the costs of lost production due to disability of patients of working age was Euros 74.82 million (indirect costs). The costs attributable to hypercholesterolemia, those that would be avoided if hypercholesterolemia were completely eliminated, amount to Euros 358.84 million in direct costs and Euros 28.31 million in indirect costs. These results confirm that hypercholesterolemia is a source of major health costs. This means that hypercholesterolemia deserves special attention from those who formulate health policy and should be given priority in implementing such policies.
publishDate 2004
dc.date.none.fl_str_mv 2004
2004-01-01T00:00:00Z
2018-04-20T14:24:24Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/32920
url http://hdl.handle.net/10451/32920
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Rev Port Cardiol 2004;23 (7-8):1037-1054
0870-2551
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Cardiologia
publisher.none.fl_str_mv Sociedade Portuguesa de Cardiologia
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833601541010882560